1790 related articles for article (PubMed ID: 11869665)
21. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials.
D'Amico AV; Chen MH; de Castro M; Loffredo M; Lamb DS; Steigler A; Kantoff PW; Denham JW
Lancet Oncol; 2012 Feb; 13(2):189-95. PubMed ID: 22112793
[TBL] [Abstract][Full Text] [Related]
22. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
23. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.
Carrie C; Magné N; Burban-Provost P; Sargos P; Latorzeff I; Lagrange JL; Supiot S; Belkacemi Y; Peiffert D; Allouache N; Dubray BM; Servagi-Vernat S; Suchaud JP; Crehange G; Guerif S; Brihoum M; Barbier N; Graff-Cailleaud P; Ruffion A; Dussart S; Ferlay C; Chabaud S
Lancet Oncol; 2019 Dec; 20(12):1740-1749. PubMed ID: 31629656
[TBL] [Abstract][Full Text] [Related]
24. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma.
Samson DJ; Seidenfeld J; Schmitt B; Hasselblad V; Albertsen PC; Bennett CL; Wilt TJ; Aronson N
Cancer; 2002 Jul; 95(2):361-76. PubMed ID: 12124837
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy for hormone-refractory prostate cancer.
Shelley M; Harrison C; Coles B; Staffurth J; Wilt TJ; Mason MD
Cochrane Database Syst Rev; 2006 Oct; (4):CD005247. PubMed ID: 17054249
[TBL] [Abstract][Full Text] [Related]
26. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
28. A systematic review of randomized trials in localized prostate cancer.
Alibhai SM; Klotz LH
Can J Urol; 2004 Feb; 11(1):2110-7. PubMed ID: 15003149
[TBL] [Abstract][Full Text] [Related]
29. Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review.
Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
BJU Int; 2015 Jul; 116(1):30-6. PubMed ID: 25523493
[TBL] [Abstract][Full Text] [Related]
30. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
Messing EM; Manola J; Yao J; Kiernan M; Crawford D; Wilding G; di'SantAgnese PA; Trump D;
Lancet Oncol; 2006 Jun; 7(6):472-9. PubMed ID: 16750497
[TBL] [Abstract][Full Text] [Related]
31. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study.
Garcia-Albeniz X; Chan JM; Paciorek A; Logan RW; Kenfield SA; Cooperberg MR; Carroll PR; Hernán MA
Eur J Cancer; 2015 May; 51(7):817-24. PubMed ID: 25794605
[TBL] [Abstract][Full Text] [Related]
32. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review.
Schmitt B; Wilt TJ; Schellhammer PF; DeMasi V; Sartor O; Crawford ED; Bennett CL
Urology; 2001 Apr; 57(4):727-32. PubMed ID: 11306391
[TBL] [Abstract][Full Text] [Related]
33. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; King M; Bowe SJ; Stockler MR; Ames A; D'Este C; Frydenberg M; Loblaw A; Malone S; Millar J; Tai KH; Turner S
Lancet Oncol; 2017 Sep; 18(9):1192-1201. PubMed ID: 28760403
[TBL] [Abstract][Full Text] [Related]
34. The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer.
Wilt TJ
J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):184-90. PubMed ID: 23271771
[TBL] [Abstract][Full Text] [Related]
35. Hormone therapy for patients with prostate carcinoma.
Klotz L
Cancer; 2000 Jun; 88(12 Suppl):3009-14. PubMed ID: 10898345
[TBL] [Abstract][Full Text] [Related]
36. Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study.
Walczak JR; Carducci MA;
Urology; 2003 Dec; 62 Suppl 1():141-6. PubMed ID: 14747052
[TBL] [Abstract][Full Text] [Related]
37. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
38. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
[TBL] [Abstract][Full Text] [Related]
39. Psychosocial interventions for men with prostate cancer: a Cochrane systematic review.
Parahoo K; McDonough S; McCaughan E; Noyes J; Semple C; Halstead EJ; Neuberger MM; Dahm P
BJU Int; 2015 Aug; 116(2):174-83. PubMed ID: 25429987
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]